Personalized Pharmacological Treatment in Schizophrenia: The Role of New Antipsychotics
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropharmacology and Neuropathology".
Deadline for manuscript submissions: closed (25 July 2022) | Viewed by 2611
Special Issue Editor
2. Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy
Interests: clinical psychiatry; schizophrenia; mood disorders; cognitive functions in severe mental illness; cognitive remediation in severe mental illness psychiatric rehabilitation in severe mental illness
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Schizophrenia is a severe mental illness associated with disability and with a significant reduction in quality of life and with large economic costs related to disability and the impact on work, family, and social functioning.
Pharmacological therapy represents the cornerstone for a successful intervention. Antipsychotic drugs differ in terms of efficacy and tolerability for individual patients and should be administered in conjunction with appropriate psychosocial and rehabilitation interventions. It is therefore necessary to identify and know the techniques of personalization of the therapy, which take into account clinical dimensions, such as negative and cognitive symptoms, and other variables, such as tolerability, adherence, psychosocial functioning, and patient preference.
This Special Issue will provide an update on pharmacological treatments for schizophrenia, from the acute phase to the maintenance and rehabilitation phase, and on the best strategies to provide each patient with a therapy that is based on the latest scientific evidence and, at the same time, adapted to the needs of individual people.
Particular attention will be paid to the need to find a favorable balance between efficacy, tolerability, and adherence to treatment.
Prof. Dr. Stefano Barlati
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- second-generation antipsychotics
- third-generation antipsychotics
- long-acting injectable (LAI) antipsychotics
- tolerability and safety
- negative symptoms
- cognitive symptoms
- functional recovery
- integrated treatment
- personalized medicine
- individualized treatment approach
